NeuroBo Pharmaceuticals Debt to Equity Ratio 1970-1969 | MTVA
Current and historical debt to equity ratio values for NeuroBo Pharmaceuticals (MTVA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. NeuroBo Pharmaceuticals debt/equity for the three months ending December 31, 1969 was 0.00.
| NeuroBo Pharmaceuticals Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.022B |
$0.000B |
|
NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States.
|
